|Bid||2.3300 x 1200|
|Ask||2.3400 x 2200|
|Day's Range||1.9800 - 2.5500|
|52 Week Range||1.4900 - 17.4100|
|Beta (5Y Monthly)||1.26|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 11, 2020 - Feb 16, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.75|
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided 2019 highlights and 2020 guidance and priorities at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco.
Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acorda's President and CEO, will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16 at 9:30am PST / 12:30pm EST.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 2) Agile Therapeutics Inc (NASDAQ: AGRX (announced the ...
Acorda Therapeutics, Inc. (Nasdaq: ACOR) ("Acorda" or the "Company") today announced it has successfully completed its previously announced private exchange of $276 million aggregate principal amount of its 1.75% Convertible Senior Notes due June 2021 (the "Existing Convertible Notes") for a combination of approximately $207 million aggregate principal amount of newly issued 6.00% Convertible Senior Secured Notes due 2024 (the "New Convertible Secured Notes ") and $55.2 million in cash. The initial conversion rate for the New Convertible Secured Notes is 285.7142 shares of the Company’s common stock per $1,000 principal amount of New Convertible Secured Notes, which is equivalent to an initial conversion price of approximately $3.50 per share, which represents a premium of approximately 97% above the Company’s closing stock price on December 20, 2019.
Acorda Therapeutics, Inc. (Nasdaq: ACOR) (the "Company") today announced that it has entered into agreements with a limited number of institutional investors who are holders of the Company’s 1.75% Convertible Senior Notes due 2021 (the "Existing Convertible Notes") to exchange $276 million aggregate principal amount of the Existing Convertible Notes for a combination of newly issued 6.00% Convertible Senior Secured Notes due 2024 (the "New Convertible Secured Notes") and cash. For each $1,000 principal amount of Existing Convertible Notes that a participating holder exchanges, the Company will deliver (i) $750 in principal amount of New Convertible Secured Notes and (ii) a cash payment of $200 (the "Exchange"). In the aggregate, the Company expects to issue approximately $207 million aggregate principal amount of New Convertible Secured Notes and $55.2 million in cash to the participating holders. The Exchange is expected to close on or about December 23, 2019.
After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms' equity portfolios as of September 30th. The results of that effort will be put on display in this article, as […]
Acorda's (ACOR) lead MS drug Ampyra is hit by generic competition in the United States, which is hurting the company's top line of late. Parkinson's disease drug Inbrija seems an ideal replacement.
Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced that its Board of Directors has elected John Kelley to serve as non-executive board Chair, effective November 25, 2019. Mr. Kelley has been a board member at Acorda since 2008. “I am delighted that John will be chairing Acorda’s board,” said Ron Cohen, M.D., Acorda's President and CEO.
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Jane Wasman, President, International & General Counsel, is resigning from the company effective at the end of this year. Ms. Wasman plans to expand her role as a member of corporate boards, and to provide consulting services within the life sciences industry. “I am proud to have been part of the team that grew Acorda from a private, clinical-stage company to a public, commercial company that has brought important new medicines to people suffering with Parkinson’s disease and multiple sclerosis,” Ms. Wasman said.
Ron Cohen has been the CEO of Acorda Therapeutics, Inc. (NASDAQ:ACOR) since 1995. First, this article will compare CEO...
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]
Acorda (ACOR) posts narrower-than-expected loss with revenues also topping estimates in the third quarter. Inbrija is also off to a promising start with sales rising sequentially.
Acorda (ACOR) delivered earnings and revenue surprises of 9.80% and 7.53%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
ARDSLEY, N.Y.-- -- Corporate restructuring implemented to reduce costs and focus resources on INBRIJA® launch INBRIJA 3Q 2019 net sales of $5 million INBRIJA approved in the European Union AMPYRA ® 3Q 2019 net sales of $38 million 2019 year end cash balance expected to be greater than $225 million Acorda Therapeutics, Inc. provided a financial update for the quarter ended September 30, 2019. “Our focus ...